Skip to main content

Table 5 Mean and standard deviation (SD) for cholesterol, quality of life, and functional scores at baseline, 12 months, and change over time

From: Towards onset prevention of cognition decline in adults with Down syndrome (The TOP-COG study): A pilot randomised controlled trial

 

Placebo

Simvastatin

Effect size

Baseline

12 months

Change

Baseline

12 months

Change

Cholesterol

5.3 (0.8)

5.4 (0.7)

0.1 (0.4)

5.1 (0.5)

4.7 (0.7)

−0.4 (0.9)

1.5 (−0.8, 3.9)

EQ-5D health utility

0.81 (0.29)

0.75 (0.29)

−0.06 (0.20)

0.54 (0.38)

0.68 (0.25)

0.14 (0.38)

0.1 (−0.7, 0.8)

ABS total score

224 (39)

214 (38)

−10 (12)

177 (50)

170 (56)

−7 (20)

−0.1 (−0.4, 0.2)

Townsend Scale total score

8.2 (3.0)

8.1 (3.4)

−0.1 (1.3)

9.3 (4.3)

11.3 (3.3)

2.0 (3.4)

0.7 (0.0, 1.4)

  1. Effect size reported as estimated between-group difference, adjusted for baseline score and stratification variables, divided by baseline SD in whole population, and reversed where necessary so that a positive effect size corresponds to a benefit for simvastatin group
  2. ABS Adaptive Behaviour Scale, EQ-5D EuroQol 5-Dimension Questionnaire